scholarly journals Pulmonary Hypertension Roundtable: Metabolic Disease and PH

2018 ◽  
Vol 17 (3) ◽  
pp. 115-120
Keyword(s):  
Metabolic Disease ◽  
Pulmonary Hypertension ◽  
Medical Center ◽  
Associate Professor ◽  
Clinical Database ◽  
Drug Induced ◽  
Methamphetamine Use ◽  
School Of Medicine ◽  
Pulmonary Arterial

On June 20, 2018, Guest Editor Anna Ryan Hemnes, MD, gathered a group of pulmonary hypertension specialists by telephone to talk about the role of metabolic disease in PH. Among the participants in the animated discussion was Roham Zamanian, MD, Director of the Adult Pulmonary Hypertension Program at Stanford University Medical Center. He directs the Vera Moulton Wall Center clinical database and biobank and focuses his research on clinical characterization and impact of novel risk factors such as methamphetamine use, and biomarkers such as insulin resistance in pulmonary arterial hypertension. Readers will recall his participation in the previous issue's roundtable on drug-induced PH. Joining Dr Zamanian were Ioana Preston, MD, Pulmonary Function Lab Director; Director, Pulmonary Hypertension Center; and Associate Professor, Tufts University School of Medicine; and Advances in Pulmonary Hypertension editor-in-chief Harrison W. Farber, MD.

scholarly journals Imatinib: A Perspective on Its Potential for PAH Patients

2012 ◽  
Vol 11 (1) ◽  
pp. 41-46
Author(s):  
R. James White ◽  
Mardi Gomberg-Maitland ◽  
Jeremy Feldman ◽  
Ioana Preston ◽  
Steve Mathai
Keyword(s):  
Pulmonary Hypertension ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Medical Center ◽  
Assistant Professor ◽  
Associate Professor ◽  
Phase Iii ◽  
Recent Phase ◽  
Hemodynamic Impairment ◽  
Pulmonary Arterial

We invited 4 experts to a telephone roundtable facilitated by guest editor Jim White, MD, PhD, on April 13, 2012, to discuss the results of the recent Phase III trial, the Imatinib in Pulmonary Arterial Hypertension (IMPRES) trial (NCT00902174). Investigators enrolled patients with pulmonary arterial hypertension with severe hemodynamic impairment at catheterization despite treatment with 2 background therapies. Patients were randomized to placebo or 200 mg imatinib twice daily for 6 months of therapy to assess efficacy. Participating in the discussion were Mardi Gomberg-Maitland, MD, MSc, Associate Professor of Medicine and Director, Pulmonary Hypertension Center, University of Chicago; Iona Preston, MD, Co-director, Pulmonary Hypertension Center, Tufts University Medical Center, Boston; Jeremy Feldman, MD, Director, Pulmonary Hypertension Program, Medical Director of Research, Arizona Pulmonary Specialists, Phoenix; Stephen Mathai, MD, MHS, Assistant Professor of Medicine, The Johns Hopkins School of Medicine, Baltimore.

scholarly journals Meeting the Challenge of Surgery and Pulmonary Hypertension: How to Manage the “Hemodynamic Environment” to Optimize Outcomes

2007 ◽  
Vol 6 (2) ◽  
pp. 92-95
Author(s):  
Richard Channick ◽  
Kenneth R. McCurry ◽  
Ronald Pearl ◽  
Stuart Rich
Keyword(s):  
Pulmonary Hypertension ◽  
Critical Care ◽  
Lung Transplantation ◽  
San Diego ◽  
Medical Center ◽  
Assistant Professor ◽  
Associate Professor ◽  
University Of California ◽  
University Of Pittsburgh ◽  
School Of Medicine

This discussion was moderated by Richard Chan-nick, MD, Associate Professor of Medicine, Pulmonary and Critical Care Division, University of California, San Diego Medical Center, San Diego, California. Panel members included Kenneth R. McCurry, MD, Assistant Professor of Surgery, Division of Cardiothoracic Surgery, Director, Lung and Heart-Lung Transplantation Programs, University of Pittsburgh Department of Surgery, Pittsburgh, Pennsylvania; Ronald Pearl, MD, PhD, Professor and Chair, Anesthesia Department, Stanford University School of Medicine, Stanford, California; and Stuart Rich, MD, Professor of Medicine, Section of Cardiology, Center for Pulmonary Hypertension, University of Chicago, Chicago, Illinois.

Sickle Cell Disease and Pulmonary Hypertension: Addressing the Mixed Pathology and Special Considerations in Diagnosis and Treatment

2007 ◽  
Vol 6 (1) ◽  
pp. 39-44
Author(s):  
Harrison W. Farber ◽  
Mark Gladwin ◽  
Evelyn M. Horn ◽  
Myung H. Park
Keyword(s):  
New York ◽  
Pulmonary Hypertension ◽  
Vascular Disease ◽  
Clinical Medicine ◽  
Medical Center ◽  
Associate Professor ◽  
Pulmonary Vascular Disease ◽  
Vascular Medicine ◽  
Blood Institute ◽  
School Of Medicine

This discussion was moderated by Evelyn M. Horn, MD, Associate Professor of Clinical Medicine and Director, Pulmonary Vascular Disease, Center for Advanced Cardiac Care, Columbia University Medical Center, New York, New York. Panel members included Harrison W. Farber, MD, Director, Pulmonary Hypertension Center, Boston Medical Center, Boston University School of Medicine; Mark Gladwin, MD, Chief, Vascular Medicine Branch, National Heart, Lung, and Blood Institute, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD; Myung H. Park, MD, Director, Pulmonary Vascular Disease Program, University of Maryland School of Medicine.

scholarly journals PH Roundtable: Pulmonary Hypertension Roundtable: Clinical Experiences With Drug- and Toxin-Related PH

2018 ◽  
Vol 17 (2) ◽  
pp. 80-85
Keyword(s):  
Pulmonary Hypertension ◽  
Medical Center ◽  
Assistant Professor ◽  
Associate Professor ◽  
Texas Southwestern Medical ◽  
Clinical Experiences ◽  
University Of Texas ◽  
School Of Medicine ◽  
Hypertension Clinic ◽  
The University

Sonja Bartolome, MD, pulmonary hypertension specialist and Director of Liver Transplant Critical Care at University of Texas Southwestern Medical Center, Dallas, facilitated a comprehensive discussion among 4 additional clinical experts regarding their experiences with the broad-ranging issues related to treating patients with drug- and toxin-related pulmonary hypertension. Joining the call on May 3, 2018, were Vinicio de Jesus Perez, MD, Assistant Professor of Medicine and staff physician and Roham Zamanian, MD, Associate Professor of Medicine and Medical Director, from the Pulmonary Hypertension Clinic at Stanford University School of Medicine; Kelly Chin, MD, Director of the Pulmonary Hypertension Center at University of Texas Southwestern Medical Center; and Konstadina Darsaklis, MD, Assistant Professor at the University of Connecticut, and cardiologist at Hartford Hospital where she started the pulmonary hypertension clinic.

scholarly journals Recapping Highlights from Pulmonary Hypertension Association Scientific Sessions and Identifying Key Issues Driving Translational Research

2004 ◽  
Vol 3 (3) ◽  
pp. 23-27
Author(s):  
Michael McGoon ◽  
Victor F. Tapson ◽  
Richard N. Channick ◽  
Valerie V. McLaughlin ◽  
Ronald J. Oudiz ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Critical Care ◽  
San Diego ◽  
Medical Center ◽  
Associate Professor ◽  
University Of Michigan ◽  
School Of Medicine ◽  
Ann Arbor ◽  
Duke University ◽  
Key Issues

This discussion was moderated by Michael McGoon, MD, Professor of Medicine and Consultant in the Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota. Participants included members of the Editorial Advisory Board of Advances in Pulmonary Hypertension: Victor F. Tapson, MD, Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina, and Editor-in-Chief of the journal; Richard N. Channick, MD, Associate Professor of Medicine, Pulmonary and Critical Care Division, University of California, San Diego Medical Center, San Diego, California; Vallerie V. McLaughlin, MD, Associate Professor of Medicine, Director, Pulmonary Hypertension Program, University of Michigan Health System, Ann Arbor, Michigan; Ronald J. Oudiz, MD, Associate Professor of Medicine, UCLA School of Medicine, and Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, Harbor-UCLA Medical Center, Torrance, California; and Ivan M. Robbins, MD, Director, Pulmonary Hypertension Center, Vanderbilt University, Nashville, Tennessee.

PH and Left Heart Disease: Defining the Clinical Dilemma

2011 ◽  
Vol 10 (1) ◽  
pp. 49-56
Author(s):  
Myung H. Park ◽  
Rene Alvarez ◽  
Teresa De Marco ◽  
Ivan Robbins ◽  
Marc Semigran
Keyword(s):  
Heart Failure ◽  
Pulmonary Hypertension ◽  
San Francisco ◽  
Medical Center ◽  
Associate Professor ◽  
Outreach Program ◽  
Pulmonary Vascular Disease ◽  
Cardiac Transplant ◽  
Transplant Program ◽  
School Of Medicine

A panel of experts convened by telephone on April 20, 2011 to discuss their experiences and recommendations regarding diagnosis and management of patients with Group 2 PH. The conversation was facilitated by Myung Park, MD, Associate Professor of Medicine and Director, Pulmonary Vascular Disease Program, Division of Cardiology at University of Maryland School of Medicine and guest editor of this issue. The participants were Rene Alvarez, MD, Associate Professor of Medicine and Director, Advanced Heart Failure/Pulmonary Hypertension Outreach Program, University of Pittsburgh School of Medicine; Teresa De Marco, MD, Professor of Medicine, Director, Heart Failure and Pulmonary Hypertension Program and Director, Heart Transplantation, University of California San Francisco Medical Center; Marc Semigran, MD, Medical Director of the Heart Failure and Cardiac Transplant Program at the Massachusetts General Hospital Center and Associate Professor of Medicine at Harvard Medical School; and Ivan Robbins, MD, Assistant Professor of Medicine and Director, Lung Transplant Program, Vanderbilt University Medical Center.

scholarly journals Exploring the Spectrum of Pathology and Treatment in Portopulmonary Hypertension: Four Experts Address the Toughest Questions

2004 ◽  
Vol 3 (2) ◽  
pp. 20-24 ◽  
Author(s):  
Ronald J. Oudiz ◽  
Michael J. Krowka ◽  
Russell Wiesner ◽  
Michael Ramsey
Keyword(s):  
Pulmonary Hypertension ◽  
Critical Care ◽  
Pain Management ◽  
Mayo Clinic ◽  
Medical Center ◽  
Associate Professor ◽  
Portopulmonary Hypertension ◽  
University Of Texas ◽  
Baylor University ◽  
School Of Medicine

This discussion was moderated by Ronald J. Oudiz, MD, Associate Professor of Medicine, David Geffen School of Medicine at UCLA, and Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, Harbor-UCLA Medical Center, Torrance, California. The participants included Michael J. Krowka, MD, Professor of Medicine, and Russell Wiesner, MD, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, and Michael Ramsay, MD, FRCA, Chairman, Department of Anesthesiology and Pain Management, Baylor University Medical Center, and Clinical Professor, Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas, Texas.

Pulmonary Arterial Hypertension Associated With Scleroderma

2008 ◽  
Vol 7 (2) ◽  
pp. 301-308
Author(s):  
Harrison Farber ◽  
Richard M. Silver ◽  
Virginia D. Steen ◽  
Charles Strange
Keyword(s):  
Pulmonary Hypertension ◽  
South Carolina ◽  
Medical Center ◽  
Pulmonary Medicine ◽  
Washington Dc ◽  
University Of South Carolina ◽  
Boston University ◽  
School Of Medicine ◽  
Pulmonary Arterial ◽  
Medical University

This discussion was moderated by Harrison (Hap) Farber, MD, Professor, Department of Medicine, Boston University School of Medicine, and Director, Pulmonary Hypertension Center, Boston Medical Center, Boston, Massachusetts. Panel members included Richard M. Silver, MD, Professor of Medicine and Pediatrics and Director of the Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina; Virginia D. Steen, MD, Proffessor of Medicine, Georgetown University, Washington, DC; and Charles Strange, MD, Professor of Pulmonary Medicine, Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina.

Using Advanced Pulmonary Hypertension Therapies in Children

2011 ◽  
Vol 10 (2) ◽  
pp. 117-124
Author(s):  
Erika Rosenzweig ◽  
Dunbar Ivy ◽  
Maurice Beghetti ◽  
Jeffrey Feinstein
Keyword(s):  
Pulmonary Hypertension ◽  
Guest Editor ◽  
Pediatric Cardiology ◽  
Associate Professor ◽  
University Hospital ◽  
Stanford University ◽  
New Therapies ◽  
University Of Toronto ◽  
University Of Colorado ◽  
School Of Medicine

On July 8, 2011, Editor-in-Chief Erika Rosenzweig convened a discussion among a group of physicians who work daily with pediatric PH patients to share their thoughts and experiences related to using new therapies with children. Contributing to the conversation were guest editor Dunbar Ivy, MD, Professor of Pediatrics, University of Colorado; Jeffrey A. Feinstein, MD, MPH, Associate Professor, Stanford University School of Medicine; Tilman Humpl, MD, PhD, Associate Professor, Pediatrics, University of Toronto; and Professor Maurice Beghetti, Head of Pediatric Subspecialties Division and Head of Pediatric Cardiology Unit, Children's University Hospital, Geneva, Switzerland.

Protocols in Heart and Lung Transplantation: An Essential Guide to Preoperative Assessment and Timing to Improve Outcomes

2004 ◽  
Vol 3 (1) ◽  
pp. 20-25
Author(s):  
Victor Tapson ◽  
Robert Frantz ◽  
John Conte
Keyword(s):  
North Carolina ◽  
Pulmonary Hypertension ◽  
Critical Care ◽  
Lung Transplantation ◽  
Medical Center ◽  
Preoperative Assessment ◽  
Assistant Professor ◽  
Associate Professor ◽  
Johns Hopkins University ◽  
Duke University

This discussion was moderated by Victor Tapson, MD, Editor-in-Chief of Advances in Pulmonary Hypertension and Associate Professor, Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina. The participants included Robert Frantz, MD, Assistant Professor of Medicine, Cardiovascular Division, Mayo Clinic, Rochester, Minnesota; and John Conte, MD, Associate Professor of Surgery and Director of Heart and Lung Transplantation, Johns Hopkins University, Baltimore, MD.

Sign in / Sign up

Export Citation Format

Share Document